Alba Therapeutics (Larazotide Acetate Assets) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Alba Therapeutics (Larazotide Acetate Assets) General Information

Description

Portfolio of assets related to a drug ingredient for celiac disease. The portfolio is comprised of assets relating to arazotide acetate, a tight junction modulator, progressing toward a Phase IIb clinical trial for the treatment of celiac disease.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
Primary Office
  • 100 International Drive 23rd Floor
  • Suite 1040
  • Baltimore, MD 21202
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Alba Therapeutics (Larazotide Acetate Assets) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alba Therapeutics (Larazotide Acetate Assets)‘s full profile, request access.

Request a free trial

Alba Therapeutics (Larazotide Acetate Assets) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alba Therapeutics (Larazotide Acetate Assets)‘s full profile, request access.

Request a free trial